222 related articles for article (PubMed ID: 26886021)
21. A flow cytometry-based reporter assay identifies macrolide antibiotics as nonsense mutation read-through agents.
Caspi M; Firsow A; Rajkumar R; Skalka N; Moshkovitz I; Munitz A; Pasmanik-Chor M; Greif H; Megido D; Kariv R; Rosenberg DW; Rosin-Arbesfeld R
J Mol Med (Berl); 2016 Apr; 94(4):469-82. PubMed ID: 26620677
[TBL] [Abstract][Full Text] [Related]
22. The functional mechanisms and clinical application of read-through drugs.
Fu Y; Shu ZY; Gu MM
Yi Chuan; 2016 Jul; 38(7):623-633. PubMed ID: 27733335
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic suppression of premature termination codons: mechanisms and clinical considerations (review).
Karijolich J; Yu YT
Int J Mol Med; 2014 Aug; 34(2):355-62. PubMed ID: 24939317
[TBL] [Abstract][Full Text] [Related]
24. PTC124 targets genetic disorders caused by nonsense mutations.
Welch EM; Barton ER; Zhuo J; Tomizawa Y; Friesen WJ; Trifillis P; Paushkin S; Patel M; Trotta CR; Hwang S; Wilde RG; Karp G; Takasugi J; Chen G; Jones S; Ren H; Moon YC; Corson D; Turpoff AA; Campbell JA; Conn MM; Khan A; Almstead NG; Hedrick J; Mollin A; Risher N; Weetall M; Yeh S; Branstrom AA; Colacino JM; Babiak J; Ju WD; Hirawat S; Northcutt VJ; Miller LL; Spatrick P; He F; Kawana M; Feng H; Jacobson A; Peltz SW; Sweeney HL
Nature; 2007 May; 447(7140):87-91. PubMed ID: 17450125
[TBL] [Abstract][Full Text] [Related]
25. [Allele-specific therapy: suppression of nonsense mutations by readthrough inducers].
Floquet C; Rousset JP; Bidou L
Med Sci (Paris); 2012 Feb; 28(2):193-9. PubMed ID: 22377308
[TBL] [Abstract][Full Text] [Related]
26. Chemical-Induced Read-Through at Premature Termination Codons Determined by a Rapid Dual-Fluorescence System Based on S. cerevisiae.
Altamura E; Borgatti M; Finotti A; Gasparello J; Gambari R; Spinelli M; Castaldo R; Altamura N
PLoS One; 2016; 11(4):e0154260. PubMed ID: 27119736
[TBL] [Abstract][Full Text] [Related]
27. Introducing sense into nonsense in treatments of human genetic diseases.
Linde L; Kerem B
Trends Genet; 2008 Nov; 24(11):552-63. PubMed ID: 18937996
[TBL] [Abstract][Full Text] [Related]
28. Emerging Personalized Opportunities for Enhancing Translational Readthrough in Rare Genetic Diseases and Beyond.
Wagner RN; Wießner M; Friedrich A; Zandanell J; Breitenbach-Koller H; Bauer JW
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047074
[TBL] [Abstract][Full Text] [Related]
29. Applying nonsense-mediated mRNA decay research to the clinic: progress and challenges.
Kuzmiak HA; Maquat LE
Trends Mol Med; 2006 Jul; 12(7):306-16. PubMed ID: 16782405
[TBL] [Abstract][Full Text] [Related]
30. Nonsense codons suppression. An acute toxicity study of three optimized TRIDs in murine model, safety and tolerability evaluation.
Corrao F; Zizzo MG; Tutone M; Melfi R; Fiduccia I; Carollo PS; Leonardo AD; Caldara G; Perriera R; Pace A; Belmonte B; Sammataro S; Pibiri I; Lentini L
Biomed Pharmacother; 2022 Dec; 156():113886. PubMed ID: 36265311
[TBL] [Abstract][Full Text] [Related]
31. Suppression of Nonsense Mutations by New Emerging Technologies.
Morais P; Adachi H; Yu YT
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575694
[TBL] [Abstract][Full Text] [Related]
32. 2-Guanidino-quinazoline promotes the readthrough of nonsense mutations underlying human genetic diseases.
Bidou L; Bugaud O; Merer G; Coupet M; Hatin I; Chirkin E; Karri S; Demais S; François P; Cintrat JC; Namy O
Proc Natl Acad Sci U S A; 2022 Aug; 119(35):e2122004119. PubMed ID: 35994666
[TBL] [Abstract][Full Text] [Related]
33. Gene selective suppression of nonsense termination using antisense agents.
Kulyté A; Dryselius R; Karlsson J; Good L
Biochim Biophys Acta; 2005 Sep; 1730(3):165-72. PubMed ID: 16135388
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic Suppression of Nonsense Mutation: An Emerging Target in Multiple Diseases and Thrombotic Disorders.
Asiful Islam M; Alam F; Kamal MA; Gan SH; Wong KK; Sasongko TH
Curr Pharm Des; 2017; 23(11):1598-1609. PubMed ID: 27875971
[TBL] [Abstract][Full Text] [Related]
35. mRNA quality control: an ancient machinery recognizes and degrades mRNAs with nonsense codons.
Behm-Ansmant I; Kashima I; Rehwinkel J; Saulière J; Wittkopp N; Izaurralde E
FEBS Lett; 2007 Jun; 581(15):2845-53. PubMed ID: 17531985
[TBL] [Abstract][Full Text] [Related]
36. Transdermal delivery of a readthrough-inducing drug: a new approach of gentamicin administration for the treatment of nonsense mutation-mediated disorders.
Shiozuka M; Wagatsuma A; Kawamoto T; Sasaki H; Shimada K; Takahashi Y; Nonomura Y; Matsuda R
J Biochem; 2010 Apr; 147(4):463-70. PubMed ID: 19910311
[TBL] [Abstract][Full Text] [Related]
37. A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes.
Liu HX; Cartegni L; Zhang MQ; Krainer AR
Nat Genet; 2001 Jan; 27(1):55-8. PubMed ID: 11137998
[TBL] [Abstract][Full Text] [Related]
38. Tobramycin is a suppressor of premature termination codons.
Altamura N; Castaldo R; Finotti A; Breveglieri G; Salvatori F; Zuccato C; Gambari R; Panin GC; Borgatti M
J Cyst Fibros; 2013 Dec; 12(6):806-11. PubMed ID: 23540394
[TBL] [Abstract][Full Text] [Related]
39. CRISPR-Pass: Gene Rescue of Nonsense Mutations Using Adenine Base Editors.
Lee C; Hyun Jo D; Hwang GH; Yu J; Kim JH; Park SE; Kim JS; Kim JH; Bae S
Mol Ther; 2019 Aug; 27(8):1364-1371. PubMed ID: 31164261
[TBL] [Abstract][Full Text] [Related]
40. Transcription-coupled RNA surveillance in human genetic diseases caused by splice site mutations.
Vaz-Drago R; Pinheiro MT; Martins S; Enguita FJ; Carmo-Fonseca M; Custódio N
Hum Mol Genet; 2015 May; 24(10):2784-95. PubMed ID: 25652404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
